Pylopass™ : a patented strain that helps reduce H. pylori
Helicobacter pylori is a Gram-, spiral-shaped bacterium with flagella. It is able to survive the acidic conditions of the stomach and adheres to the gastrointestinal walls.
This bacterium is pathogenic to the gastrointestinal mucosa and causes gastritis, ulcers and even stomach cancer. However, H. pylori infection can also be asymptomatic. In particular, it is estimated that at least 50% of the population is infected and only 15-20% show symptoms.
Pylopass™ is an inactivated strain of Lactobacillus reuteri, which helps reduce H. pylori contamination in the stomach. Pylopass™ forms aggregates with H. Pylori and allows its excretion through the digestive tract.
In a clinical study of 24 patients with asymptomatic H. pylori contamination versus placebo, a reduction in H. pylori contamination was observed after oral supplementation with 200 mg Pylopass™ for 14 days1.
(1) Holz C et al., (2014) Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: A pilot study. Probiotics & Antimicro. Prot. 7: 91-100.
1. Pylopass™ is a trademark of Novozymes A/S Denmark www.pylopass.com.